Point72 Hong Kong Ltd Takes $1.91 Million Position in Humana Inc. (NYSE:HUM)

Point72 Hong Kong Ltd purchased a new stake in Humana Inc. (NYSE:HUM - Free Report) during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 7,535 shares of the insurance provider's stock, valued at approximately $1,912,000.

A number of other hedge funds have also bought and sold shares of the business. Dodge & Cox increased its holdings in shares of Humana by 106.7% during the fourth quarter. Dodge & Cox now owns 10,198,040 shares of the insurance provider's stock worth $2,587,345,000 after purchasing an additional 5,264,045 shares during the period. Vanguard Group Inc. increased its stake in Humana by 15.8% during the 4th quarter. Vanguard Group Inc. now owns 12,829,210 shares of the insurance provider's stock worth $3,254,899,000 after acquiring an additional 1,751,857 shares during the period. Norges Bank acquired a new position in Humana in the 4th quarter valued at $416,202,000. Pzena Investment Management LLC raised its holdings in Humana by 44.0% in the 4th quarter. Pzena Investment Management LLC now owns 3,609,382 shares of the insurance provider's stock valued at $915,736,000 after acquiring an additional 1,103,132 shares in the last quarter. Finally, Boston Partners raised its holdings in Humana by 435.8% in the 4th quarter. Boston Partners now owns 1,098,702 shares of the insurance provider's stock valued at $279,236,000 after acquiring an additional 893,637 shares in the last quarter. 92.38% of the stock is owned by institutional investors.

Humana Trading Up 3.9%

Shares of NYSE HUM traded up $9.20 during trading on Monday, reaching $247.16. The company had a trading volume of 2,094,086 shares, compared to its average volume of 1,768,621. The stock has a market cap of $29.83 billion, a P/E ratio of 24.84, a PEG ratio of 2.05 and a beta of 0.49. The company's fifty day moving average price is $262.94 and its 200-day moving average price is $269.57. The company has a quick ratio of 1.76, a current ratio of 1.76 and a debt-to-equity ratio of 0.68. Humana Inc. has a 12 month low of $212.45 and a 12 month high of $406.46.

Humana (NYSE:HUM - Get Free Report) last posted its quarterly earnings data on Wednesday, April 30th. The insurance provider reported $11.58 EPS for the quarter, topping analysts' consensus estimates of $10.07 by $1.51. The company had revenue of $32.11 billion for the quarter, compared to analyst estimates of $32 billion. Humana had a return on equity of 11.70% and a net margin of 1.02%. The firm's quarterly revenue was up 8.4% on a year-over-year basis. During the same period in the previous year, the firm earned $7.23 earnings per share. As a group, research analysts expect that Humana Inc. will post 16.47 earnings per share for the current year.

Humana Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, July 25th. Stockholders of record on Friday, June 27th will be given a $0.885 dividend. This represents a $3.54 annualized dividend and a dividend yield of 1.43%. The ex-dividend date of this dividend is Friday, June 27th. Humana's dividend payout ratio (DPR) is presently 25.04%.

Wall Street Analysts Forecast Growth

HUM has been the subject of several analyst reports. Oppenheimer lifted their price objective on Humana from $300.00 to $310.00 and gave the company an "outperform" rating in a report on Thursday, May 1st. Guggenheim assumed coverage on shares of Humana in a report on Wednesday, April 9th. They set a "buy" rating and a $326.00 price target for the company. Raymond James upgraded shares of Humana from a "market perform" rating to an "outperform" rating and set a $315.00 price target on the stock in a research report on Thursday, May 1st. Morgan Stanley cut their target price on Humana from $301.00 to $285.00 and set an "equal weight" rating for the company in a research note on Wednesday, February 12th. Finally, Robert W. Baird raised their target price on Humana from $270.00 to $300.00 and gave the company a "neutral" rating in a report on Tuesday, April 15th. Seventeen equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company's stock. According to data from MarketBeat, the company presently has a consensus rating of "Hold" and a consensus target price of $286.81.

About Humana

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.